A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs

Inclusion Criteria: * Moderate to severe active RA of ≥6 months duration * DAS28 \>3.2 * Inadequate response to a stable dose of non-biologic DMARD for ≥2 months * Those receiving oral corticosteroids must have been at stable dose for ≥25 days in the 28 days prior to first study treatment Exclusion Criteria: * Rheumatic autoimmune disease other than RA * History of or current inflammatory joint disease other than RA * Previous treatment with alkylating agents or total lymphoid irradiation * Intra-articular or parenteral corticosteroids within 6 weeks prior to Baseline * Previous treatment with any cell-depleting therapies * American College of Rheumatology (ACR) Functional Class IV